HIV disease progression in Australia in the time of combination antiretroviral therapies
- 1 November 1998
- journal article
- Published by AMPCo in The Medical Journal of Australia
- Vol. 169 (9) , 469-472
- https://doi.org/10.5694/j.1326-5377.1998.tb123370.x
Abstract
To examine the effect of recent developments in antiretroviral therapy on HIV disease progression and survival. Retrospective cohort study. Two cohorts of people with HIV were defined retrospectively from the records of a large immunology laboratory. The first cohort were subjects whose CD4+ T cell counts had dropped to 200 x 10(6)/L during 1990, and the second were subjects whose CD4+ T cell counts had dropped to 200 x 10(6)/L in 1994. HIV disease progression and survival was determined over a minimum three years of follow-up for each cohort (i.e., 1990-1993; 1994-1997). 346 subjects were included in the analysis (193 subjects from 1990 and 153 from 1994). The relative risk of progression to AIDS in the 1994 cohort compared with the 1990 cohort was 0.57 (95% confidence interval, 0.35-0.91; P = 0.018) and the relative risk of death was 0.20 (95% confidence interval, 0.08-0.49; P < 0.001). There were 43% fewer AIDS cases and 80% fewer deaths in the time following the increased availability of combination antiretroviral therapy in Australia.Keywords
This publication has 8 references indexed in Scilit:
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trialThe Lancet, 1997
- Impact of Epidemic and Individual Heterogeneity on the Population Distribution of Disease Progression Rates: An Example from Patient Populations in Trials of Human Immunodeficiency Virus InfectionAmerican Journal of Epidemiology, 1996
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- Development of AIDS in a cohort of HIV‐seropositive homosexual men in AustraliaThe Medical Journal of Australia, 1990